Loading company
Just reported
From Adaptive Biotechnologies's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$83.9M
-11% y/y
+17% q/q
Guided
—
No guide given
Actual
$0.02
-67% y/y
Guided
—
No guide given
Actual
-$457K
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Adaptive Biotechnologies is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.$265.9BA+
IDXXIdexx Laboratories Inc.$55.4BA+
IQVIQVIA Holdings Inc.$45.2BA
ILMNIllumina, Inc.$32.2BA+
LHLabcorp Holdings Inc.$30.2BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now ABuilt from Adaptive Biotechnologies Corporation’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
Company outlook: revenue of $276M to $286M for Fiscal year 2026 — up 1.5% on a year earlier
Grade C-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 28 quarters of Adaptive Biotechnologies Corporation’s grade history. The other 26 go back to February 2020.
